AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36308120 — intervention group
Group type: EXPERIMENTAL
Intervention: MSICS with cauterization using wetfield bipolar cautery with 4 amperes power (Group 1, n = 75)
Number of subjects: 150
Study 36308120 — intervention group
Group type: COMPARATOR
Intervention: No cauterization (Group 2, n = 75)
Number of subjects: 150
Study 34219679 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS of the visual cortex (n=7)
Number of subjects: 56
Study 34219679 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS/rtACS (n=8)
Number of subjects: 56
Study 34219679 — intervention group
Group type: EXPERIMENTAL
Intervention: rtACS alone (n=8)
Number of subjects: 56
Study 34219679 — intervention group
Group type: COMPARATOR
Intervention: sham (n=7)
Number of subjects: 56
Study 34219679 — intervention group
Group type: COMPARATOR
Intervention: sham (n=9)
Number of subjects: 56
Study 34219679 — intervention group
Group type: COMPARATOR
Intervention: sham (n=8)
Number of subjects: 56
Study 33372070 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU (treatment as usual)
Number of subjects: 0
Study 33372070 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + LMP (lifestyle modification programme)
Number of subjects: 0
Study 33372070 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + LMP + ICTs (information and communication technologies)
Number of subjects: 0
Study 34767764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (n=72)
Number of subjects: 225
Study 34767764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=70)
Number of subjects: 225
Study 34767764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 225
Study 34767764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 33228744 — intervention group
Group type: EXPERIMENTAL
Intervention: Active psychological treatments for depression (specific treatments not detailed)
Number of subjects: 58
Study 33228744 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 58
Study 33228744 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of trial design
Number of subjects: 58
Study 35713803 — intervention group
Group type: EXPERIMENTAL
Intervention: High esthetic food
Number of subjects: 0
Study 35713803 — intervention group
Group type: EXPERIMENTAL
Intervention: Low esthetic food
Number of subjects: 0
Study 33640861 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuranolone (30mg)
Number of subjects: 89
Study 32481364 — intervention group
Group type: EXPERIMENTAL
Intervention: Huangqi Guizhi Wuwu decoction
Number of subjects: 360
Study 32481364 — intervention group
Group type: COMPARATOR
Intervention: Huangqi Guizhi Wuwu decoction mimetic agent
Number of subjects: 360
Study 35664468 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS active stimulation
Number of subjects: 37
Study 35664468 — intervention group
Group type: COMPARATOR
Intervention: tDCS sham stimulation
Number of subjects: 37
Study 33269819 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-targeted mechanical ventilation (VG-AC)
Number of subjects: 20
Study 33269819 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled mechanical ventilation (PC-AC)
Number of subjects: 20
Study 34951112 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVENT (standard iBWL + prevention-focused training)
Number of subjects: 95
Study 34951112 — intervention group
Group type: COMPARATOR
Intervention: STANDARD (standard iBWL)
Number of subjects: 95
Study 34951112 — intervention group
Group type: COMPARATOR
Intervention: PROMOTE (standard iBWL + promotion-focused training)
Number of subjects: 95
Study 34128447 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Exercise Training (METP)
Number of subjects: 36
Study 34128447 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening Exercise Training (METP)
Number of subjects: 36
Study 34128447 — intervention group
Group type: COMPARATOR
Intervention: Both Morning and Evening METP
Number of subjects: 36
Study 32675291 — intervention group
Group type: EXPERIMENTAL
Intervention: WBF-011
Number of subjects: 76
Study 32675291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 34193072 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermo Fisher TaqPath™ Combo Kit
Number of subjects: 300
Study 34193072 — intervention group
Group type: COMPARATOR
Intervention: Cepheid Xpert® Xpress SARS-CoV-2 assay
Number of subjects: 300
Study 34619050 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI + hydroxyzine
Number of subjects: 53
Study 34619050 — intervention group
Group type: COMPARATOR
Intervention: SSRI only
Number of subjects: 53
Study 33929215 — intervention group
Group type: EXPERIMENTAL
Intervention: Random measurements in three-qubit systems
Number of subjects: 0
Study 33929215 — intervention group
Group type: EXPERIMENTAL
Intervention: Random measurements in higher-dimensional two-particle systems
Number of subjects: 0
Study 35678636 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-negative design (TND)
Number of subjects: 7029
Study 35678636 — intervention group
Group type: COMPARATOR
Intervention: Matched case-control design (MCC)
Number of subjects: 7029
Study 33979232 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use negative pressure wound therapy (sNPWT)
Number of subjects: 0
Study 33979232 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 33543449 — intervention group
Group type: EXPERIMENTAL
Intervention: 3Mix-MP
Number of subjects: 44
Study 33543449 — intervention group
Group type: COMPARATOR
Intervention: Calcium Hydroxide
Number of subjects: 44
Study 36395435 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 415
Study 36395435 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 415
Study 32552523 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Therapeutic hypothermia (ETH) with primary PCI
Number of subjects: 50
Study 32552523 — intervention group
Group type: COMPARATOR
Intervention: Control group (primary PCI only)
Number of subjects: 50
Study 32459600 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy
Number of subjects: 310
Study 32459600 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice (Idelalisib plus Rituximab)
Number of subjects: 310
Study 32459600 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice (Bendamustine plus Rituximab)
Number of subjects: 310
Study 32459600 — intervention group
Group type: COMPARATOR
Intervention: Idelalisib plus Rituximab
Number of subjects: 310
Study 32459600 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus Rituximab
Number of subjects: 310
Study 34367045 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced training group
Number of subjects: 106
Study 34367045 — intervention group
Group type: COMPARATOR
Intervention: Standard training group
Number of subjects: 106
Study 34367045 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 33183325 — intervention group
Group type: EXPERIMENTAL
Intervention: TPVB group (n = 45)
Number of subjects: 90
Study 33183325 — intervention group
Group type: COMPARATOR
Intervention: GA group (n = 45)
Number of subjects: 90
Study 35953881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 828
Study 35953881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/daclatasvir
Number of subjects: 828
Study 35953881 — intervention group
Group type: COMPARATOR
Intervention: Control (standard prevention advice)
Number of subjects: 828
Study 33706247 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone withdrawal group (n = 112)
Number of subjects: 221
Study 33706247 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbitone continued group (n = 109)
Number of subjects: 221
Study 36292193 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory technique
Number of subjects: 280
Study 36292193 — intervention group
Group type: COMPARATOR
Intervention: Tracheal suction
Number of subjects: 280
Study 32847461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined omega-3 and Korean red ginseng supplementation
Number of subjects: 120
Study 32847461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34364670 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control with amiodarone/cardioversion
Number of subjects: 523
Study 34364670 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 523
Study 34364670 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 523
Study 33236662 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fixed-dose hydroxyurea (20 mg/kg/day)
Number of subjects: 220
Study 33236662 — intervention group
Group type: COMPARATOR
Intervention: Low fixed-dose hydroxyurea (10 mg/kg/day)
Number of subjects: 220
Study 35510925 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based phone application
Number of subjects: 248
Study 35510925 — intervention group
Group type: COMPARATOR
Intervention: Standard training (video and paper copy)
Number of subjects: 248
Study 32079861 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 220
Study 32079861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol plus Simvastatin
Number of subjects: 220
Study 34263351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral vestibulopathy patients
Number of subjects: 37
Study 34263351 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 37
Study 32629535 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thoracic sympathectomy (Group TS)
Number of subjects: 66
Study 32629535 — intervention group
Group type: COMPARATOR
Intervention: Sham (Group Sham)
Number of subjects: 66
Study 34183348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trials with specified progression criteria
Number of subjects: 160
Study 34183348 — intervention group
Group type: COMPARATOR
Intervention: Peer reviewer reports
Number of subjects: 160
Study 33857678 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 0
Study 33857678 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging assessments (MRI & PET)
Number of subjects: 0
Study 33857678 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trial costs
Number of subjects: 0
Study 35090033 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AE, n=21)
Number of subjects: 84
Study 35090033 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (CE, n=20)
Number of subjects: 84
Study 35090033 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaccustomed exercise
Number of subjects: 84
Study 35090033 — intervention group
Group type: COMPARATOR
Intervention: Systemic inflammation
Number of subjects: 84
Study 35090033 — intervention group
Group type: COMPARATOR
Intervention: Physical performance measures
Number of subjects: 84
Study 35090033 — intervention group
Group type: COMPARATOR
Intervention: Tumour necrosis factor-α
Number of subjects: 84
Study 35090033 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-6
Number of subjects: 84
Study 34320708 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine for nerve blockage
Number of subjects: 126
Study 34320708 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of 50 mg dexketoprofen
Number of subjects: 126
Study 32487875 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation
Number of subjects: 0
Study 32487875 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate predictive modeling
Number of subjects: 0
Study 32487875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0
Study 35158325 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point method loading conditions
Number of subjects: 30
Study 35158325 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-point method loading conditions
Number of subjects: 30
Study 35158325 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point method excluding the data point most declining the coefficient of determination
Number of subjects: 30
Study 35158325 — intervention group
Group type: COMPARATOR
Intervention: Control group (sport students)
Number of subjects: 30
Study 33619896 — intervention group
Group type: EXPERIMENTAL
Intervention: Carillon device
Number of subjects: 83
Study 33619896 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 83
Study 32717295 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 39
Study 32717295 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 39
Study 35933417 — intervention group
Group type: EXPERIMENTAL
Intervention: We-PAP (couples-based sleep health intervention)
Number of subjects: 0
Study 35933417 — intervention group
Group type: COMPARATOR
Intervention: Information Control (IC)
Number of subjects: 0
Study 33438206 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of medications with limited benefit in hospice patients (cancer and non-cancer diagnoses)
Number of subjects: 0
Study 33438206 — intervention group
Group type: COMPARATOR
Intervention: Prescribing oral anticoagulants in the emergency department
Number of subjects: 0
Study 33438206 — intervention group
Group type: EXPERIMENTAL
Intervention: Conducting electronic medication reconciliation
Number of subjects: 0
Study 33438206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification of antihypertensive medications
Number of subjects: 0
Study 34409538 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 214
Study 34409538 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 214
Study 34244982 — intervention group
Group type: EXPERIMENTAL
Intervention: Variance minimisation (VM) procedure
Number of subjects: 0
Study 34244982 — intervention group
Group type: COMPARATOR
Intervention: Random assignment procedure
Number of subjects: 0
Study 36472543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop (HCL)
Number of subjects: 302
Study 33199081 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of continuous wave CO2 laser and fractional ablative CO2 laser (Group 1)
Number of subjects: 40
Study 33199081 — intervention group
Group type: COMPARATOR
Intervention: Fractional ablative CO2 laser alone (Group 2)
Number of subjects: 40
Study 33078725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam administered by parents
Number of subjects: 60
Study 33078725 — intervention group
Group type: COMPARATOR
Intervention: Intranasal midazolam administered by doctors
Number of subjects: 60
Study 35392881 — intervention group
Group type: EXPERIMENTAL
Intervention: T-shaped toothbrush
Number of subjects: 100
Study 35392881 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 100
Study 33301652 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard computer-assisted cognitive training (CACT)
Number of subjects: 25
Study 33301652 — intervention group
Group type: EXPERIMENTAL
Intervention: CACT enhanced with music (CACT+A)
Number of subjects: 25
Study 32252049 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactofem oral probiotic capsule (500 mg daily for 2 months)
Number of subjects: 70
Study 32252049 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 70
Study 35470105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (50,000 IU weekly for 8 weeks)
Number of subjects: 62
Study 35470105 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (identical for 8 weeks)
Number of subjects: 62
Study 34229752 — intervention group
Group type: EXPERIMENTAL
Intervention: i-PRF
Number of subjects: 346
Study 34229752 — intervention group
Group type: COMPARATOR
Intervention: Blood clot
Number of subjects: 346
Study 34688374 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab plus celecoxib (n=17)
Number of subjects: 34
Study 34688374 — intervention group
Group type: COMPARATOR
Intervention: Toripalimab monotherapy (n=17)
Number of subjects: 34
Study 34335740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.3 mg/kg bolus after induction, followed by 0.2 mg/kg/hr infusion for up to 24 hours)
Number of subjects: 35
Study 34335740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 35
Study 34335740 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 35
Study 35077207 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous conditioned serum (ACS) dressing
Number of subjects: 30
Study 35077207 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) dressing
Number of subjects: 30
Study 32012051 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day pain reporting
Number of subjects: 14
Study 32012051 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day pain reporting
Number of subjects: 14
Study 32012051 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-week pain reporting
Number of subjects: 14
Study 32012051 — intervention group
Group type: EXPERIMENTAL
Intervention: As-and-when pain reporting
Number of subjects: 14
Study 32012051 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative findings from interviews
Number of subjects: 14
Study 35352134 — intervention group
Group type: EXPERIMENTAL
Intervention: Western diet‐like high‐carbohydrate meal (WDHC)
Number of subjects: 60
Study 35352134 — intervention group
Group type: EXPERIMENTAL
Intervention: Western diet‐like high-fat meal (WDHF)
Number of subjects: 60
Study 35352134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet‐like meal (MED)
Number of subjects: 60
Study 35352134 — intervention group
Group type: EXPERIMENTAL
Intervention: High inflammation group (CRP ≥ 2.0 mg/L)
Number of subjects: 60
Study 35352134 — intervention group
Group type: COMPARATOR
Intervention: Low inflammation group (CRP < 2.0 mg/L)
Number of subjects: 60
Study 35142162 — intervention group
Group type: COMPARATOR
Intervention: Low EGFR expression in HPV16 positive tumors (89.29%)
Number of subjects: 0
Study 35142162 — intervention group
Group type: COMPARATOR
Intervention: PIK3CA mutations in HPV16 positive (7.14%) and HPV negative (2.5%) cancers
Number of subjects: 0
Study 35142162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low expression of APOBEC3B in HPV16 positive patients
Number of subjects: 0
Study 35142162 — intervention group
Group type: EXPERIMENTAL
Intervention: APOBEC3B, Akt, and pAkt(Thr308) levels in HPV negative patients
Number of subjects: 0
Study 35142162 — intervention group
Group type: EXPERIMENTAL
Intervention: pAkt(Thr308) levels in HPV negative patients
Number of subjects: 0
Study 35142162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low T stage, low pAkt(Thr308) expression, active HPV16 infection, and female gender
Number of subjects: 0
Study 32208108 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary cooperative clinical trials program for advanced Hodgkin's disease
Number of subjects: 0
Study 32208108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative clinical trials program
Number of subjects: 0
Study 32208108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hodgkin's disease trial
Number of subjects: 0
Study 36195807 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (activator, orally)
Number of subjects: 24
Study 36195807 — intervention group
Group type: EXPERIMENTAL
Intervention: rifampicin (inducer, orally)
Number of subjects: 24
Study 36195807 — intervention group
Group type: EXPERIMENTAL
Intervention: oral voriconazole (inhibitor)
Number of subjects: 24
Study 36195807 — intervention group
Group type: EXPERIMENTAL
Intervention: intravenous voriconazole (inhibitor)
Number of subjects: 24
Study 36195807 — intervention group
Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 24
Study 33637230 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 (selurampanel) 100mg TID
Number of subjects: 0
Study 33637230 — intervention group
Group type: EXPERIMENTAL
Intervention: BGG492 (selurampanel) 50mg TID
Number of subjects: 0
Study 33637230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32127545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration (standard nasal spray)
Number of subjects: 0
Study 32127545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration (nebulizer)
Number of subjects: 0
Study 32127545 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration
Number of subjects: 0
Study 35713224 — intervention group
Group type: EXPERIMENTAL
Intervention: AI (DENTAL MONITORING®)
Number of subjects: 53
Study 35713224 — intervention group
Group type: EXPERIMENTAL
Intervention: AIHC (DENTAL MONITORING® + human counseling)
Number of subjects: 53
Study 35713224 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 53
Study 32188915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day for 7 days
Number of subjects: 23
Study 32188915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 33843086 — intervention group
Group type: EXPERIMENTAL
Intervention: 20G fenestrated catheter
Number of subjects: 26
Study 33843086 — intervention group
Group type: COMPARATOR
Intervention: 18G standard catheter
Number of subjects: 26
Study 35533701 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug regimen (ivermectin 200 μg/kg, diethylcarbamazine 6 mg/kg, albendazole 400 mg)
Number of subjects: 4563
Study 35533701 — intervention group
Group type: COMPARATOR
Intervention: Two-drug regimen (diethylcarbamazine 6 mg/kg, albendazole 400 mg)
Number of subjects: 4563
Study 35533701 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-drug regimen
Number of subjects: 4563
Study 35533701 — intervention group
Group type: COMPARATOR
Intervention: Two-drug regimen
Number of subjects: 4563
Study 33434451 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 monthly videoconference‐tailored coaching sessions with an advanced practice nurse or social worker, participation in patient appointments via videoconference, access to a website designed for DCGs.
Number of subjects: 302
Study 33434451 — intervention group
Group type: COMPARATOR
Intervention: Access to the DCG website only.
Number of subjects: 302
Study 33434451 — intervention group
Group type: COMPARATOR
Intervention: Access to the DCG website and participation in patient appointments via videoconference, but no coaching sessions.
Number of subjects: 302